Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$12.50 USD
+0.50 (4.17%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $12.48 -0.02 (-0.16%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Ocular Therapeutix, Inc. has a market cap of $1.91B, which represents its share price of $12.00 multiplied by its outstanding shares number of 159.30M. As a small-cap company, OCUL's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
OCUL 12.50 +0.50(4.17%)
Will OCUL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OCUL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCUL
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
OCUL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
Other News for OCUL
Scotiabank Lowers Price Target for Ocular Therapeutix (OCUL) | OCUL Stock News
Ocular Therapeutix price target lowered to $20 from $22 at Scotiabank
Ocular Therapeutix price target lowered by $2 at Scotiabank, here's why
Ocular Therapeutix Inc (OCUL) Q2 2025 Earnings Call Highlights: Strategic Advances and ...
Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript